Tag Archives: selexipag

December, 2015

  • 28 December

    FDA Approves Actelion’s Uptravi for Pulmonary Arterial Hypertension

    ALLSCHWIL, SWITZERLAND – 22 December 2015 – Actelion (SIX: ATLN) announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag), originally discovered and synthesized by Nippon Shinyaku, for the treatment of pulmonary arterial hypertension …